Journal of mucopolysaccharidosis and rare diseases

Association for Research of MPS and Rare Diseases (뮤코다당증연구학회)
권호 표지
DOI QR코드

DOI QR Code

Growth Hormone Therapy in Children with Prader-Willi Syndrome

  • Im, Minji (Department of Pediatrics, Sungae General Hospital)
  • Received : 2021.03.20
  • Accepted : 2021.04.20
  • Published : 2021.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Prader-Willi syndrome is a complicated genetic disorder caused by a mutation on chromosome 15q11-13. The disease results in morbid obesity due to hyperphagia, growth disturbance, multiple endocrine problems from hypopituitarism, developmental delay, and cognitive or behavioral problems. Recombinant human growth hormone has been used to improve body composition and muscle mass, which plays a main role in treating patients with Prader-Willi syndrome. We describe previous studies showing the efficacy and safety of growth hormone treatment in children with Prader-Willi syndrome and provide treatment guidelines. Growth hormone therapy could be beneficial for children with Prader-Willi syndrome and improve their quality of life.

Keywords

References

  1. CrinoA, Fintini D, Bocchini S, Grugni G. Obesity management in Prader-Willi syndrome: current perspectives. Diabetes Metab Syndr Obes 2018;11:579-93. https://doi.org/10.2147/DMSO.S141352
  2. Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi Syndrome [Internet]. Seattle (WA): GeneReviews®; c1998 [cited 2021 Feb 20]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1330/.
  3. Lindgren AC, Ritzen EM. Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group. Acta Paediatr Suppl 1999;88:109-11. https://doi.org/10.1111/j.1651-2227.1999.tb14416.x
  4. Grugni G, Giardino D, CrinoA, Malvestiti F, Ballarati L, Di Giorgio G, et al. Growth hormone secretion among adult patients with Prader-Willi syndrome due to different genetic subtypes. J Endocrinol Invest 2011;34:493-7. https://doi.org/10.3275/7203
  5. Diene G, Mimoun E, Feigerlova E, Caula S, Molinas C, Grandjean H, et al. Endocrine disorders in children with Prader-Willi syndrome--data from 142 children of the French database. Horm Res Paediatr 2010;74:121-8. https://doi.org/10.1159/000313377
  6. Craig ME, Cowell CT, Larsson P, Zipf WB, Reiter EO, Albertsson Wikland K, et al. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol (Oxf) 2006;65:178-85. https://doi.org/10.1111/j.1365-2265.2006.02570.x
  7. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med 2012;14:10-26. https://doi.org/10.1038/gim.0b013e31822bead0
  8. Yang X. Growth hormone treatment for Prader-Willi syndrome: A review. Neuropeptides 2020;83:102084. https://doi.org/10.1016/j.npep.2020.102084
  9. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002;87:1581-5. https://doi.org/10.1210/jc.87.4.1581
  10. de Lind van Wijngaarden RF, de Klerk LW, Festen DA, Duivenvoorden HJ, Otten BJ, Hokken-Koelega AC. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. J Clin Endocrinol Metab 2009;94:1274-80. https://doi.org/10.1210/jc.2008-1844
  11. Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome. J Clin Endocrinol Metab 2010;95:1131-6. https://doi.org/10.1210/jc.2009-1389
  12. Corripio R, Tubau C, Calvo L, Brun C, Capdevila N, Larramona H, et al. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study. J Pediatr Endocrinol Metab 2019;32:879-84. https://doi.org/10.1515/jpem-2018-0539
  13. Reus L, Pelzer BJ, Otten BJ, Siemensma EP, van Alfen-van der Velden JA, Festen DA, et al. Growth hormone combined with child-specific motor training improves motor development in infants with Prader-Willi syndrome: a randomized controlled trial. Res Dev Disabil 2013;34:3092-103. https://doi.org/10.1016/j.ridd.2013.05.043
  14. Lafortuna CL, Minocci A, Capodaglio P, Gondoni LA, Sartorio A, Vismara L, et al. Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with prader-willi syndrome. J Clin Endocrinol Metab 2014;99:1816-24. https://doi.org/10.1210/jc.2013-3607
  15. Hoybye C, Hilding A, Jacobsson H, Thoren M. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2003;58:653-61. https://doi.org/10.1046/j.1365-2265.2003.01769.x
  16. Lo ST, Festen DA, Tummers-de Lind van Wijngaarden RF, Collin PJ, Hokken-Koelega AC. Beneficial Effects of LongTerm Growth Hormone Treatment on Adaptive Functioning in Infants With Prader-Willi Syndrome. Am J Intellect Dev Disabil 2015;120:315-27. https://doi.org/10.1352/1944-7558-120.4.315
  17. Hoybye C, Thoren M, Bohm B. Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome. J Intellect Disabil Res 2005;49:245-52. https://doi.org/10.1111/j.1365-2788.2005.00641.x
  18. Lo ST, Siemensma EP, Festen DA, Collin PJ, Hokken-Koelega AC. Behavior in children with Prader-Willi syndrome before and during growth hormone treatment: a randomized controlled trial and 8-year longitudinal study. Eur Child Adolesc Psychiatry 2015;24:1091-101. https://doi.org/10.1007/s00787-014-0662-4
  19. Wolfgram PM, Carrel AL, Allen DB. Long-term effects of recombinant human growth hormone therapy in children with Prader-Willi syndrome. Curr Opin Pediatr 2013;25:509-14. https://doi.org/10.1097/MOP.0b013e328362c7a2
  20. Eiholzer U. Deaths in Children with Prader-Willi Syndrome. Hormone Research in Paediatrics 2005;63:33-9. https://doi.org/10.1159/000082745
  21. Bakker B, Maneatis T, Lippe B. Sudden Death in PraderWilli Syndrome: Brief Review of Five Additional Cases. Hormone Research in Paediatrics 2007;67:203-4. https://doi.org/10.1159/000097928
  22. Eiholzer U, Nordmann Y, l'Allemand D. Fatal Outcome of Sleep Apnoea in PWS during the Initial Phase of Growth Hormone Treatment. Hormone Research in Paediatrics 2002;58(suppl 3):24-6. https://doi.org/10.1159/000066478
  23. Festen DA, de Weerd AW, van den Bossche RA, Joosten K, Hoeve H, Hokken-Koelega AC. Sleep-related breathing disorders in prepubertal children with Prader-Willi syndrome and effects of growth hormone treatment. J Clin Endocrinol Metab 2006;91:4911-5. https://doi.org/10.1210/jc.2006-0765
  24. de Lind van Wijngaarden RF, Cianflone K, Gao Y, Leunissen RW, Hokken-Koelega AC. Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment. J Clin Endocrinol Metab 2010;95:1758-66. https://doi.org/10.1210/jc.2009-0656
  25. Deal CL, Tony M, Hoybye C, Allen DB, Tauber M, Christiansen JS. GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 2013;98:E1072-87. https://doi.org/10.1210/jc.2012-3888
  26. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:4183-97. https://doi.org/10.1210/jc.2008-0649
  27. Grugni G, Sartorio A, CrinoA. Growth hormone therapy for Prader-willi syndrome: challenges and solutions. Ther Clin Risk Manag 2016;12:873-81. https://doi.org/10.2147/TCRM.S70068